Anaplastic lymphoma kinase inhibitor-associated myositis

Abstract

Anaplastic lymphoma kinase (ALK) inhibitors have been used in patients with non-small cell lung cancer (NSCLC) harboring EML4-ALK fusion gene.1 Severe skeletal muscle adverse events of ALK inhibitors, such as muscle weakness, have seldom been reported.2,3 Herein, we describe a patient who showed a severe skeletal muscle deficit after the administration of the ALK inhibitor, alectinib, and was successfully treated by corticosteroids without withdrawal from the cancer therapy.